Markets

  • Influenza globally occurs with an annual incidence rate estimated at 5%–10% in adults. Illnesses can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically-ill patients)
  • Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths
  • Vaccination efficiently covers only 23% to 30% of the Western population
  • Oseltamivir (TamifluTM) is -despite strong resistances- the leading approved anti-viral drug to treat influenza

sales

Competition

Novel derivatives of neuraminidase inhibitors and polymerase inhibitors in development are based on the same mechanism as Tamiflu, thus suffer rapid resistance development as well.

DAS181 removes the cellular receptors for the virus, the sialic acids from the cell surface. The compound is still in early clinical development

Transcription factor NF-kappa B is in early clinical development. No results have been published yet.

MEK inhibitors show strong promise as first-in-class antiviral drugs that target cellular kinases, providing all the advantages that are unmatched by current approaches.